6-Methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-Methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride
• 英文别名: 6-Methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b] indole hydrochloride；6-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;hydrochloride
• 化学式: C₁₃H₁₃F₃N₂*ClH
• 分子量: 290.716
• InChiKey: HBBVJFJZTWRPFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.56
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  27.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-methyl-3-(trifluoromethyl)phenyl)hydrazine 、 4-氧代哌啶酮盐酸盐 在 盐酸 作用下， 以 异丙醇 为溶剂， 反应 15.17h， 生成 6-Methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride
  参考文献：
  名称：

  Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists

  摘要：

  本申请描述了化合物，包括所有药用盐、前药、溶剂合物和其立体异构体，根据式I，包括至少一种根据式I的化合物的药物组合物，以及可选择地至少一种额外的治疗剂，以及使用根据式I的化合物治疗与调节5-羟色胺受体相关的各种疾病、状况和紊乱的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、葡萄糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和胃肠道疾病。

  公开号：

  US20070027178A1

文献信息

• SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1910361A2

  公开（公告）日：2008-04-16
• [EN] SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS<br/>[FR] TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES SUBSTITUÉS EN TANT QU'AGONISTES ET ANTAGONISTES DU RÉCEPTEUR DE SÉROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007016353A2

  公开（公告）日：2007-02-08

  [EN] The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
  [FR] La présente invention concerne des composés, notamment la totalité des sels pharmaceutiquement acceptables, des promédicaments, des solvat et des stéréoisomères de ceux-ci, selon la Formule I, les compositions pharmaceutiques, comprenant au moins un composé selon la Formule I et facultativement au moins un agent thérapeutique supplémentaire ainsi que les procédés de traitement de diverses maladies et troubles associés à la modulation des récepteurs de sérotonine tels que, par exemple : les maladies métaboliques, ce qui inclut mais sans s'y limiter l'obésité, le diabète, les complications diabétiques, l'athérosclérose, la diminution de la tolérance au glucose et la dyslipidémie ; les maladies du système nerveux central, ce qui inclut mais sans s'y limiter, l'anxiété, la dépression, les troubles obsessionnels compulsifs, la panique, la psychose, la schizophrénie, les troubles du sommeil, les troubles sexuels et les phobies sociales ; les céphalées ; la migraine ainsi que les troubles gastro-intestinaux en utilisant les composés selon la Formule I.
• Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
  申请人：Lee Taekyu

  公开号：US20070027178A1

  公开（公告）日：2007-02-01

  The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I

  本申请描述了化合物，包括所有药用盐、前药、溶剂合物和其立体异构体，根据式I，包括至少一种根据式I的化合物的药物组合物，以及可选择地至少一种额外的治疗剂，以及使用根据式I的化合物治疗与调节5-羟色胺受体相关的各种疾病、状况和紊乱的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、葡萄糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和胃肠道疾病。